Developing strategies for prevention and treatment of recurrent HBV in liver transplantation.

[1]  E. Schiff,et al.  Efficacy of lamivudine in controlling hepatitis B virus recurrence after liver transplantation. , 1998, Transplantation.

[2]  M. Gaffey,et al.  Improved clinical outcomes with liver transplantation for hepatitis B-induced chronic liver failure using passive immunization. , 1998, Annals of surgery.

[3]  S. Schalm.  Clinical implications of lamivudine resistance by HBV , 1997, The Lancet.

[4]  K. Reddy,et al.  Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation , 1997, The Lancet.

[5]  B. C. Wong,et al.  Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: A placebo‐controlled trial , 1997, Hepatology.

[6]  R. Tubiana,et al.  Effects of Lamivudine on Replication of Hepatitis B Virus in HIV-Infected Men , 1996, Annals of Internal Medicine.

[7]  D. Tyrrell,et al.  Mutation in HBV RNA‐dependent DNA polymerase confers resistance to lamivudine in vivo , 1996, Hepatology.

[8]  P. Pierce,et al.  Potential role of lamivudine (3TC) in the clearance of chronic hepatitis B virus infection in a patient coinfected with human immunodeficiency virus type. , 1996, Clinical Infectious Diseases.

[9]  E. Elias,et al.  Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine , 1996, Hepatology.

[10]  D. Tyrrell,et al.  Generation of duck hepatitis B virus polymerase mutants through site-directed mutagenesis which demonstrate resistance to lamivudine [(--)-beta-L-2', 3'-dideoxy-3'-thiacytidine] in vitro , 1996, Antimicrobial agents and chemotherapy.

[11]  T. Pruett,et al.  Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization. , 1996, Transplantation.

[12]  E. Schiff,et al.  A preliminary trial of lamivudine for chronic hepatitis B infection. , 1995, The New England journal of medicine.

[13]  T. Poynard,et al.  Efficacy of lamivudine on replication of hepatitis B virus in HIV-infected patients , 1995, The Lancet.

[14]  W. Bechstein,et al.  Long-term follow-up of hepatitis B virus-infected recipients after orthotopic liver transplantation. , 1994, Transplantation.

[15]  G. Alexander,et al.  Liver transplantation in European patients with the hepatitis B surface antigen. , 1993, The New England journal of medicine.

[16]  S. Davies,et al.  High-level expression of hepatitis B viral antigens in fibrosing cholestatic hepatitis. , 1992, Gastroenterology.

[17]  D. Samuel,et al.  Passive immunoprophylaxis after liver transplantation in HBsAg-positive patients , 1991, The Lancet.

[18]  D. V. van Thiel,et al.  Orthotopic liver transplantation for patients with hepatitis B virus–related liver disease , 1991, Hepatology.

[19]  D. V. van Thiel,et al.  Evolution of hepatitis B virus liver disease after hepatic replacement. Practical and theoretical considerations. , 1990, The American journal of pathology.